Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in France / NCT07631039
Starting soon Not applicable

LOGOGRAM: Validation of Allergy Care Flowcharts in Primary Care: Experience From Occitanie

NCT07631039 · tracked via the Priya Life Science France tracker
Phase
Not applicable
Started
2026-09
Last updated
2026-06-05

Condition(s) studied

Allergy

Investigational drug(s) / intervention(s)

Implementation of an innovative tool based around AI-automated decision trees on an application

Implementation of an innovative tool based around AI-automated decision trees on an application: The application provides immediate access to the algorithms (decision trees). Investigators can access a dedicated interface and enter participant data, including the suspected diagnosis, symptoms, acute episode or history of allergic disease, and the medical decision made (diagnosis, therapeutic management, or referral to a specialist). Management options based on the five algorithms are then generated to support physicians in the diagnosis and management of allergic diseases.

Study summary

This study, aimed at validating decision trees developed through collaboration between general practitioners and allergists, seeks to provide French data to optimize care pathways for patients with allergic diseases from the primary care level and to reduce the delays and negative consequences associated with incorrect diagnoses. Most patients with allergic conditions are initially seen in primary care, often during exacerbations. Although allergies, in their many clinical forms, account for approximately 6-8% of primary care consultations, clinicians frequently receive little or no formal training in this field and may not be fully aware of the latest evidence, associated risks, or appropriate referral pathways. These gaps can significantly affect the quality of care and patients' quality of life, while also contributing to higher morbidity and mortality. In this context, the European Academy of Allergy and Clinical Immunology established a multidisciplinary task force to transform existing allergy guidelines into simple, practical, and accessible tools to facilitate diagnosis and management in primary care. The group developed five decision trees covering asthma, anaphylaxis, drug allergy, food allergy, rhinitis, and urticaria to support primary care physicians and other non-specialists in managing patients with symptoms suggestive of allergic or hypersensitivity reactions. The results of this project will be directly applicable to the daily clinical practice of general practitioners in France and could serve as a model for replication in other regions and countries, although adaptations may be required depending on national healthcare systems.

Eligibility

Sex
ALL
Min age
1 Year
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Patients with suspected asthma, anaphylaxis, drug allergy, food allergy, rhinitis and urticaria. * Patients aged 1 year or older at inclusion, registered with a health insurance plan. * Patient or legal representative of the minor patient who agrees to participate in the research. Exclusion Criteria: * Adults placed under guardianship or curatorship. * Patients already followed by an allergist and/or a specialist doctor for their allergies. * Patients who participate in a clinical research study relating to an antiallergic medication, immunosuppressant, immunomodulator in the year preceding their consultation visit with the GP.

Primary outcome measure(s)

Trial sites (10)

FacilityCityRegionStatus
Msp Espace Sante Servian Béziers Occitanie
MSP Universitaire Avicenne Cabestany Occitanie
Msp Montpellier -Cevenne Montpellier Occitanie
Msp Narbo Ouest Narbonne Occitanie
Msp Charles Gide Nîmes Occitanie
Msp Beau Art Perpignan Occitanie
MSP Calypso Roujan Occitanie
Département Universitaire de Médecine Générale MSPU CHU Montpellier Saint-Georges-dOrques Occitanie
Msp Sud Minevoir Saint-Marcel-sur-Aude Occitanie
MSP Pézenas-Tourbes Tourbes Occitanie

More University Hospital, Montpellier trials in France

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07631039 on ClinicalTrials.gov ↗ ← All trials in France